In late 2013, Aaron Davis presented his poster on Gout treatment costs and regional variations. Contact me if you want a copy. email@example.com
Metabolic Markets accepted for publication again!
Last year M2 did considerable work in gout. In partnership with our friends at Symphony Health, M2’s Aaron Davis’s abstract has been accepted to the American College of Rheumatology’s annual conference. The title: “Assessing The Increasing Costs To Manage Patients With Gout By State” Gout is a surprisingly costly disease state that goes unrecognized / …
Metabolic Markets Published in CAPG Health magazine
Working with our partners at MEMOTEXT, we had an article published on the clinical and economic burden of patient non-compliance in diabetes and cardiovascular disease. Page 32.
Metabolic Markets in action today @ Epidemic of Obesity meeting
M2 co-founder Damon Tanton is speaking on several obesity related topics today and tomorrow in Washington D.C. If you are there, let us know!
Visit the new www.Metabolicmarkets.com
We have re-vamped our site. Come see what is new!
The burden of poor patient compliance in CVD risk and diabetes – an M2 whitepaper
In association with our partners at MEMOTEXT, Metabolic Markets has produced a whitepaper review on the clinical and economic burden of poor patient compliance in cardiovascular disease risk and diabetes. Click HERE to access the whitepaper. Some important data points about patient compliance in diabetes Patients with medical possession ratios less than 80% had 2.5 …
Poor patient compliance – the great consistent – inconsistency
Years ago when I was a forecasting geek, I could build the best model ever, based on sound data, and well thought through assumptions. Time after time, the most controversial subject would be the patient compliance/adherence assumption. Brand leadership wanting to show a bigger number would always argue that “patients are going to love this …
Compliance tied to employee production
The healthcare costs of compliance have been generally well characterized. Some interesting work done by CVS pharmacy tied chronic care medication compliance into employee absenteeism. In short, employees who take their medications are less likely to miss work, up to a difference of 7 days per year. Doesn’t sound like much, but aggregated for a …
MEMOTEXT® and Metabolic Markets, LLC announce strategic partnership
MEMOTEXT and Metabolic Markets have entered into a strategic partnership, integrating MEMOTEXT’s best-in-class patient adherence platform into the Metabolic Markets’ client offerings. “Patient compliance and adherence has long been one of the biggest challenges in chronic disease management. MEMOTEXT’s unique, customized programs aimed at individualizing and increasing patient engagement, result in improved compliance and …
The next item up for bid: Amylin Pharmaceuticals, who, if anyone, wants them?
The rumor mill has cranked up once again with a leaked story that Amylin has brought Goldman Sachs and Credit Suisse aboard to market the sale of the company. The usual suspects have been identified by the anointed experts analyst world: BMS, Sanofi, Takeda, Merck, AstraZeneca. Has Amylin leaked their interests to sell in …